Dana Farber choosing Pax for blood cancer in the brain has highly significant implications for the drug.
Make no mistake this is a blood cancer (the company, "a little bit" used the word brain cancer)......sure its in the brain, but PCNSL is a blood cancer, no doubt about that. (my research - about 5 hours alone on the type of cancer)
Pax for blood cancer in a clinical trial, after some major approved cancer drugs, including PI3k drugs - had previously been tried.
I am not suggesting Pax is already a done deal with approved from the FDA - no, but the drug has done enough across a broad range of research, studies and other clinical trials - now/todayto be opened up in 15 or 20 FDA clinical trials in PI3 actionable cancers - OUTSIDE of the brain.......(So that in one sentence is again what I think of the worth of the drug. )
Again just rereading my story from earlier today, regarding PTEN and PI3K inhibitors for prostrate cancers - that is a nice story from only yesterday, and explains things well. It might help to explain such a big call just made.
It would be nice to get contrarian calls, based on factual logic - but is that possible.... are those drugs in the prostrate story better equipped to do the job than Pax ? (not "calls" for needle to be cautious, thanks)
KZA Price at posting:
$1.25 Sentiment: Buy Disclosure: Held
